EGFR and cancer: To further demonstrate the reliability of MDP, we found a statistical significant association between the EGFR inhibitor Gefitinib (Iressa) (p-value = 0.03) [26] and the tyrosine kinase inhibitor Selumetinib (p-value = 0.03) with somatic missense EGFR mutations in CCLE cancer cell lines (Figure 3B).